Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
7.66
+0.24 (3.23%)
Apr 28, 2025, 9:32 AM EDT - Market open
Myriad Genetics Market Cap
Myriad Genetics has a market cap or net worth of $706.03 million as of April 28, 2025. Its market cap has decreased by -61.23% in one year.
Market Cap
706.03M
Enterprise Value
721.81M
1-Year Change
-61.23%
Ranking
Category
Stock Price
$7.66
Market Cap Chart
Since December 1, 1998, Myriad Genetics's market cap has increased from $102.30M to $706.03M, an increase of 590.16%. That is a compound annual growth rate of 7.59%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Apr 25, 2025 | 677.50M | -45.72% |
Dec 31, 2024 | 1.25B | -20.67% |
Dec 29, 2023 | 1.57B | 33.81% |
Dec 30, 2022 | 1.18B | -46.65% |
Dec 31, 2021 | 2.20B | 48.19% |
Dec 31, 2020 | 1.49B | -26.57% |
Dec 31, 2019 | 2.03B | -6.80% |
Dec 31, 2018 | 2.17B | -8.61% |
Dec 29, 2017 | 2.38B | 108.51% |
Dec 30, 2016 | 1.14B | -62.13% |
Dec 31, 2015 | 3.01B | 21.14% |
Dec 31, 2014 | 2.49B | 58.51% |
Dec 31, 2013 | 1.57B | -29.30% |
Dec 31, 2012 | 2.22B | 25.03% |
Dec 30, 2011 | 1.77B | -15.91% |
Dec 31, 2010 | 2.11B | -15.93% |
Dec 31, 2009 | 2.51B | -18.54% |
Dec 31, 2008 | 3.08B | 50.95% |
Dec 31, 2007 | 2.04B | 64.00% |
Dec 29, 2006 | 1.24B | 93.29% |
Dec 30, 2005 | 643.90M | -6.71% |
Dec 31, 2004 | 690.20M | 98.11% |
Dec 31, 2003 | 348.40M | -0.17% |
Dec 31, 2002 | 349.00M | -71.84% |
Dec 31, 2001 | 1.24B | -34.15% |
View and export this data all the way back to 1998.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 794.31B |
UnitedHealth Group | 381.06B |
Johnson & Johnson | 371.93B |
AbbVie | 329.14B |
Novo Nordisk | 272.76B |
Abbott Laboratories | 223.47B |
AstraZeneca | 214.65B |
Novartis AG | 211.71B |